Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinomaПодробнее

Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trialПодробнее

Study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinomaПодробнее

CheckMate 9ER: glycoproteomic biomarkers for nivolumab and cabozantinib in aRCCПодробнее

Javelin Renal 101 Updated ResultsПодробнее

JAVELIN Renal 101: avelumab plus axitinib improve PFS for advanced renal cell cancerПодробнее

Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCCПодробнее

Kidney Cancer Biomarker Insights: JAVELIN Renal 101Подробнее

JAVELIN Renal 101: combination approach for advanced RCC patients | Laurence AlbigesПодробнее

Expert comment on the JAVELIN Renal 101 trial | Markus JoergerПодробнее

Dr. Choueiri on the Subgroup Analysis of the JAVELIN Renal 101 Trial in RCCПодробнее

Results from CABOSUN, METEOR and JAVELINПодробнее

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinibПодробнее

Kidney Cancer JAVELIN 101: Toni Choueiri, MD | Dana-Farber Cancer InstituteПодробнее

Prof Jon Haanan on the JAVELIN studyПодробнее

Efficacy of PD-L1 inhibitor avelumab in NEPC/AVPCПодробнее

Updates on JAVELIN renal 101: primary treatment for patientsПодробнее

JAVELIN Bladder 100 trial: Biomarkers for maintenance avelumab in metastatic urothelial cancerПодробнее

Combining avelumab and axitinib in advanced renal cell carcinoma (RCC)Подробнее